These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 27733159)

  • 1. Moderate-intensity statin therapy seems ineffective in primary cardiovascular prevention in patients with type 2 diabetes complicated by nephropathy. A multicenter prospective 8 years follow up study.
    Sasso FC; Lascar N; Ascione A; Carbonara O; De Nicola L; Minutolo R; Salvatore T; Rizzo MR; Cirillo P; Paolisso G; Marfella R;
    Cardiovasc Diabetol; 2016 Oct; 15(1):147. PubMed ID: 27733159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of effect of aspirin in primary CV prevention in type 2 diabetic patients with nephropathy: results from 8 years follow-up of NID-2 study.
    Sasso FC; Marfella R; Pagano A; Porta G; Signoriello G; Lascar N; Minutolo R; Carbonara O; Persico M; Piscione F; De Nicola L; Torella R; Paolisso G
    Acta Diabetol; 2015 Apr; 52(2):239-47. PubMed ID: 25109286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy.
    Menon V; Kumar A; Patel DR; John JS; Wolski KE; McErlean E; Riesmeyer JS; Weerakkody G; Ruotolo G; Cremer PC; Nicholls SJ; Lincoff AM; Nissen SE
    J Am Heart Assoc; 2020 Jan; 9(1):e014328. PubMed ID: 31852422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
    Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
    JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin use reduces cardiovascular events and all-cause mortality amongst Chinese patients with type 2 diabetes mellitus: a 5-year cohort study.
    Fung CSC; Wan EYF; Chan AKC; Lam CLK
    BMC Cardiovasc Disord; 2017 Jun; 17(1):166. PubMed ID: 28645252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative contributions of statin intensity, achieved low-density lipoprotein cholesterol level, and statin therapy duration to cardiovascular risk reduction in patients with type 2 diabetes: population based cohort study.
    Kim JY; Choi J; Kim SG; Kim NH
    Cardiovasc Diabetol; 2022 Feb; 21(1):28. PubMed ID: 35193571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study.
    Ramos R; Comas-Cufí M; Martí-Lluch R; Balló E; Ponjoan A; Alves-Cabratosa L; Blanch J; Marrugat J; Elosua R; Grau M; Elosua-Bayes M; García-Ortiz L; Garcia-Gil M
    BMJ; 2018 Sep; 362():k3359. PubMed ID: 30185425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients.
    Stam-Slob MC; Visseren FL; Wouter Jukema J; van der Graaf Y; Poulter NR; Gupta A; Sattar N; Macfarlane PW; Kearney PM; de Craen AJ; Trompet S
    Clin Res Cardiol; 2017 Jan; 106(1):58-68. PubMed ID: 27554244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
    Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
    Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Perspectives from the CREDO-Kyoto registry cohort-2.
    Natsuaki M; Furukawa Y; Morimoto T; Nakagawa Y; Ono K; Kaburagi S; Inada T; Mitsuoka H; Taniguchi R; Nakano A; Kita T; Sakata R; Kimura T;
    Circ J; 2012; 76(6):1369-79. PubMed ID: 22447012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study.
    Zhu L; Hayen A; Bell KJL
    Cardiovasc Diabetol; 2020 Mar; 19(1):28. PubMed ID: 32138746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary prevention with statins and incident diabetes in hypertensive patients at high cardiovascular risk.
    Izzo R; de Simone G; Trimarco V; Giudice R; De Marco M; Di Renzo G; De Luca N; Trimarco B
    Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1101-6. PubMed ID: 23419735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triglycerides and risk of cardiovascular events in statin-treated patients with newly diagnosed type 2 diabetes: a Danish cohort study.
    Kristensen FPB; Christensen DH; Mortensen MB; Maeng M; Kahlert J; Sørensen HT; Thomsen RW
    Cardiovasc Diabetol; 2023 Jul; 22(1):187. PubMed ID: 37495999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC; Botros FT; Atisso CM; Sager PT
    Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuing statins or not in the elderly? Study protocol for a randomized controlled trial.
    Bonnet F; Bénard A; Poulizac P; Afonso M; Maillard A; Salvo F; Berdaï D; Salles N; Rousselot N; Marchi S; Hayes N; Joseph JP
    Trials; 2020 Apr; 21(1):342. PubMed ID: 32307005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensity of statin therapy and primary prevention of cardiovascular in Korean patients with dyslipidemia.
    Song SO; Kang MJ; Suh S
    Medicine (Baltimore); 2024 Mar; 103(11):e37536. PubMed ID: 38489707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors.
    Gazzaruso C; Solerte SB; Pujia A; Coppola A; Vezzoli M; Salvucci F; Valenti C; Giustina A; Garzaniti A
    J Am Coll Cardiol; 2008 May; 51(21):2040-4. PubMed ID: 18498958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Statin Therapy and Dose on Cardiovascular and Limb Outcomes in Peripheral Arterial Disease: A Systematic Review and Meta-analysis.
    Sofat S; Chen X; Chowdhury MM; Coughlin PA
    Eur J Vasc Endovasc Surg; 2021 Sep; 62(3):450-461. PubMed ID: 34389230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of soluble tumor necrosis factor receptors 1 and 2 with nephropathy, cardiovascular events, and total mortality in type 2 diabetes.
    Carlsson AC; Östgren CJ; Nystrom FH; Länne T; Jennersjö P; Larsson A; Ärnlöv J
    Cardiovasc Diabetol; 2016 Feb; 15():40. PubMed ID: 26928194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to statins and its impact on clinical outcomes: a retrospective population-based study in China.
    Zhao B; He X; Wu J; Yan S
    BMC Cardiovasc Disord; 2020 Jun; 20(1):282. PubMed ID: 32522146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.